Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
Jason R WestinR Eric DavisLei FengFredrick B HagemeisterRaphael SteinerJee Hun LeeLuis FayadLoretta NastoupilSairah AhmedMaria A RodriguezMichelle FanaleFelipe SamaniegoSwaminathan P IyerRanjit NairYasuhiro OkiNathan FowlerMichael L WangMan Chun John MaFrancisco VegaTimothy McDonnellChelsea PinnixDonna GriffithYang LuSanjit O TewariRyan SunDavid W ScottChristopher R FlowersSattva S NeelapuMichael R GreenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Smart Start is the first study, to our knowledge, to treat newly diagnosed DLBCL with a targeted therapy combination before chemotherapy. RLI produced a high ORR, and RLI with chemotherapy resulted in durable responses. This establishes the potential for developing biologically driven and noncytotoxic first-line therapies for DLBCL.